Skip to content
Screener

Enliven Therapeutics ELVN Q2 2025 earnings

Reported August 13, 2025 · Before market open

EPS-$0.49Beat by $0.04
EPS estimate-$0.53

Next report

Date not yet announced

Financials

Q2 2025

Income statement

See full
Operating income-$28.6M-16.2%
Net income-$25.3M-27.0%
EPS (diluted)-$0.49-19.5%

Balance sheet

See full
Cash & equivalents$119.4M+23.3%
Total debt$580.0K+243%
Total equity$488.5M+60.2%
Total assets$503.9M+54.1%

Cash flow

See full
Operating cash flow-$17.1M+16.5%
CapEx$139.0K+6,850%
Free cash flow-$17.2M+15.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.25B+11.1%
Enterprise value$1.13B+10.0%

Returns & leverage

See full
Return on equity-25.3%-2.5pp
Debt / equity0×0.0×
Current ratio32.6×+18.2×

FAQ

When did Enliven Therapeutics report Q2 2025 earnings?
Enliven Therapeutics (ELVN) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Enliven Therapeutics's Q2 2025 revenue and EPS?
Enliven Therapeutics reported eps of $-0.49 for Q2 2025.
Did Enliven Therapeutics beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.53 by $0.04.
How did Enliven Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 19.5% from $-0.41.
Where can I find Enliven Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-179837) and the 10-Q periodic report (0001193125-25-179845) directly on SEC EDGAR. The filing index links above go to sec.gov.